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ABSTRACT 
Acid-sensing ion channels (ASICs) are proton-activated cation channels that are expressed in a 
variety of neuronal and non-neuronal tissues. As proton-gated channels, they have been implicated 
in many pathophysiological conditions where pH is perturbed. Venom derived compounds 
represent the most potent and selective modulators of ASICs described to date, and thus have been 
invaluable as pharmacological tools to study ASIC structure, function, and biological roles. There 
are now ten ASIC modulators described from animal venoms, with those from snakes and spiders 
favouring ASIC1, while the sea anemones preferentially target ASIC3. Some modulators, such as 
the prototypical ASIC1 modulator PcTx1 have been studied in great detail, while some of the newer 
members of the club remain largely unstudied. Here we review the current state of knowledge on 
venom derived ASIC modulators, with a particular focus on their molecular interaction with ASICs, 
what they have taught us about channel structure, and what they might still reveal about ASIC 
function and pathophysiological roles. 
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1. Introduction to acid-sensing ion channels 
Acid-sensing ion channels (ASICs) were first discovered at the sequence level in 1996 
(Garcia-Anoveros et al., 1997; Price et al., 1996; Waldmann et al., 1996) and shortly thereafter 
identified as proton-gated cation channels (Waldmann et al., 1997). They are abundantly 
expressed throughout mammalian neuronal and non-neuronal tissues, where they are primary 
acid-sensors. There are four human ASIC (hASIC) genes (ASIC1–4, renamed from the 
previous ACCN designation) encoding at six major subunits (ASIC1a, ASIC1b, ASIC2a, 
ASIC2b, ASIC3, and ASIC4). The ASIC1 and ASIC2 genes are alternatively spliced to produce 
“a” and “b” isoforms, which differ in the N-terminal third of the protein (Bässler et al., 2001; 
Lingueglia et al., 1997). Additionally, there are three functional splice variants of hASIC3 (a, b 
and c), which do not appear to be present in rodents (Delaunay et al., 2012). Three ASIC 
subunits combine to form functional homo- and heterotrimers (Jasti et al., 2007) with different 
biophysical properties and expression profiles (Cristofori-Armstrong et al., 2015; Gründer and 
Pusch, 2015; Hesselager et al., 2004). The rapid, transient peak-current of ASICs is selective 
for Na+ over K+ by a factor of ~10, and desensitises within seconds in the continued presence 
of an acidic pH. That is, ion channels enter a non-conducting state and fail to respond to 
additional acidification (Waldmann et al., 1997). ASIC activation is pH-dependent (i.e., current 
amplitude increases with decreasing pH until a maximal current amplitude is reached) (Wu et 
al., 2004). Prolonged exposure of ASICs to mildly acidic pH or slow acidification results in 
steady-state desensitisation (SSD) without the channel entering an observable open conducting 
state (Babini et al., 2002). This has been proposed to be due to the rapid kinetics of 
desensitisation and a slow on-rate for protons at lower concentrations, thereby masking any 
transition through an open state (Gründer and Pusch, 2015). The model proposed by Gründer 
and Pusch is however qualitative in nature, and it was noted that the possibility of a simple 
closed to desensitised transition cannot be excluded. In this alternative, and possibly simplest 
explanation, the gating of ASICs does allow a direct transition from the closed to the 
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desensitised state, as desensitisation is more pH-sensitive than activation. In this case, upon 
slow or mild acidification, the channels would desensitise before activation could take place 
(thus any observable current). Whereas during rapid acidification, channel activation is 
observable due to the faster kinetics of activation compared to desensitisation (however 
channel opening would still be inherently influenced by the rate of desensitisation and likely be 
underestimated). Nevertheless, the complete picture of ASIC gating remains to be solved and 
remains an area of intense research interest.  
A massive leap in our understanding of the structure of ASICs occurred when the crystal 
structure of chicken ASIC1 (ASIC1a sequence homologue) was published in 2007 (Jasti et al., 
2007), even though the construct used for crystallisation was a non-functional channel with 
heavily truncated N- and C-termini. The structure revealed the trimeric nature of ASICs, and 
showed that each subunit consists of short intracellular N- and C-termini and two hydrophobic 
transmembrane (TM) domains separated by a large extracellular domain of ~370 residues. The 
structure of an individual subunit was described as resembling a hand clenched around a ball 
comprising a wrist, palm, finger, knuckle, thumb, and β-ball domains (see Figure 1A). 
Subsequently a less severely N-terminally truncated and functional cASIC1 construct, named 
∆13 cASIC1, was crystallised in the presumed desensitised state and differed from the previous 
structure primarily in the orientation of the TM domains (Gonzales et al., 2009). Recent 
cASIC:venom peptide co-crystal structures have provided further insights into ASIC structure 
and gating and are discussed in Sections 2.1.2 and 2.5.2 (Figure 1C & D).  
Despite the growing interest in ASICs, and the increasing volume of work being produced 
in the field, there are still many unanswered questions. Venom derived compounds have 
greatly enhanced our understanding of ASICs to date, and are likely to play an important role 
in the future. In this review, we will focus on our current understanding of these venom-
derived compounds, and how they have provided critical information on ASIC structure and 
function. Please refer to these reviews for more in-depth coverage of recent advances in genetic 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5 
models (Lin et al., 2015) and biophysical properties (Gründer and Pusch, 2015) of ASICs, and 
more comprehensive coverage of the in vivo use of ASIC modulating venom peptides to study 
the pathological roles of ASICs (Baron et al., 2013; Baron and Lingueglia, 2015).  
 
2. Venom peptides targeting ASICs 
Many endogenous and exogenous modulators of ASICs have now been discovered, 
however essentially all the known small molecule ligands are either non-selective and/or lack 
potency, or are not yet sufficiently characterised (Rash, 2017). Although the lack of truly 
selective modulators of ASICs has made it difficult to tease out the relative importance of 
specific ASIC subtypes, the most interesting and selective tools available to date have all come 
from animal venoms.  
 
2.1. PcTx1 
2.1.1. The prototypical, selective ASIC inhibitor 
PcTx1 (also known as π-TRTX-Pc1a) is a 40-residue peptide isolated from the venom of the 
Trinidad chevron tarantula Psalmopoeus cambridgei (Escoubas et al., 2000) (Figure 2A). 
Although isolated as the first highly potent and selective inhibitor of homomeric ASIC1a (rat 
IC50 ~1 nM conditioned at pH 7.45 and human IC50 ~3 nM conditioned at pH 7.2), PcTx1 has 
subsequently been shown to also inhibit currents in ASIC1a/2b co-expressing cells (mouse IC50 
~3 nM) and heteromeric rat ASIC1a/2a channels (by ~35–85% at 50 nM conditioned at pH 
6.95 depending on trimer composition) (Joeres et al., 2016; Sherwood et al., 2011). At higher 
concentrations PcTx1 potentiates ASIC1b (rat EC50 ~100 nM) (Chen et al., 2006) and is an 
agonist and/or potentiator of cASIC1 depending on the conditions used (EC50 ~10–189 nM) 
(Hoagland et al., 2010; Smith and Gonzales, 2014). The NMR structure of PcTx1 (Figure 2B), 
which was first solved in 2003 and further refined in 2011, revealed the presence of an 
inhibitor cysteine knot (ICK) motif and that the dominant β-hairpin loop (loop 4), which 
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presents some of the key pharmacophore residues, is highly flexible (Escoubas et al., 2003; 
Saez et al., 2011). 
PcTx1 binds in a state-dependent manner to both ASIC1a and ASIC1b. It acts as a gating 
modifier of ASIC1a by increasing the channel's apparent affinity for protons, thereby rendering 
the channel inactive at resting physiological pH of 7.4 (Chen et al., 2005). This effect can be 
seen as a shift in the steady-state desensitisation (SSD) and activation curves to less acidic pH 
values. It is in fact this mechanism of action that renders PcTx1 less potent at human as 
compared to rodent ASIC1a (Sherwood and Askwith, 2008). The SSD of hASIC1a is 
inherently less sensitive to pH, thus a higher concentration of PcTx1 is required to capture the 
channel in a desensitised (and non-conducting) state when conditioned at pH 7.4. In agreement 
with this, mutation of five residues of hASIC1a to the equivalent mouse ASIC1a (mASIC1a) 
residues makes the pH sensitivity of the species variants equal. This mutant hASIC1a channel 
regains the same sensitivity to PcTx1 as that of mASIC1a (Sherwood and Askwith, 2008). The 
potentiation of ASIC1b currents by PcTx1 is due to a large shift in the activation curve to less 
acidic pH (whereas the SSD curve is largely unaffected) and concomitant slowing of 
desensitisation as seen by an increase in the decay time constant in the presence of PcTx1 
(Chen et al., 2006). The agonist/potentiating effect of PcTx1 on cASIC1 has so far not been 
studied in much detail but is likely through stabilising the open state of the channel by 
enhancing activation, slowing desensitisation or both. Interestingly, studies of PcTx1’s 
functional effect on cASIC1 revealed a biphasic response whereby application of PcTx1 at pH 
7.35 transiently opened the channel, followed by only partial desensitisation to a long-lasting, 
persistent current (Smith and Gonzales, 2014). The potentiating effect of PcTx1 at rASIC1b 
and cASIC1 may be partly explained by the “pH sensor-trapping model” proposed by Salinas 
et al. (Salinas et al., 2014). Using ASIC chimeras and mutant channels, it was shown that loss 
of PcTx1 contacts with either the palm and/or β-ball regions of rASIC1a led to current 
potentiation via movement induced by peptide binding to the thumb domain. This complex 
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pharmacology shows that PcTx1 can preferentially stabilise several states of ASICs that are 
dependent on the external environment and inherent gating properties of the channel being 
studied. It also highlights that very small differences in the molecular interaction between 
peptide and channel can greatly change the functional effect of a ligand.  
The substantial subtype, species, and condition-dependent functional effects of PcTx1 are 
likely to make it a very difficult peptide to manipulate for use as a truly selective 
pharmacological tool or therapeutic lead, and also warrant caution when interpreting results 
from in vivo experiments. These factors also warrant caution when interpreting ASIC 
electrophysiology data. Due to its subtype-dependent effects on channel opening and 
desensitisation, the rate of solution exchange in experimental setups can have a substantial 
effect on the observed activity and relative potencies. For example, a slow solution exchange 
of the recording chamber coupled with recording in large oocyte cells (where much of our 
PcTx1 information has been derived) could lead to inaccurate interpretation of observations if 
the peptide application is slower than the inherent gating time scale of the ASIC in question. 
These are less likely to be issues with fast solution exchange as achieved using whole-cell 
recordings from small cells or macro-patch recordings. Nevertheless, it is important for authors 
to include such details when reporting their data, and for readers when assessing the 
conclusions made about an ASIC modulators functional effects.  
Using alanine-scanning mutagenesis of PcTx1 we determined the primary functional 
pharmacophore at rat (r) ASIC1a to comprise the residues Trp7, Trp24, Phe30, Arg26, Arg27, 
and Arg28 (Saez et al., 2015; Saez et al., 2011). These findings agree with the co-crystal 
structures of PcTx1:cASIC1, however the structures showed many more close contacts 
between the peptide and channel (Baconguis and Gouaux, 2012; Dawson et al., 2012) (Figure 
3A–C). From these studies we hypothesise that the peptide binding is largely mediated through 
the hydrophobic patch comprised of residues Trp7, Trp24, Phe30 (with contributions from the 
C4 sidechain of R26) while the functional consequence of binding is due to the positively 
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charged, basic cluster of Arg26, Arg27, and Arg28, that form interactions with proton-sensing 
residues in the acidic pocket (Saez et al., 2015) (Figure 3B), however, this theory requires 
some direct binding experiments to confirm. An unexpected outcome of these peptide 
mutagenesis studies was the discovery of some potent ASIC1a potentiating molecules, the 
PcTx1 mutants R26A and F30A. The subtype selectivity and mechanism of action of these 
peptides is yet to be determined, nevertheless they appear to represent new pharmacological 
tools with activity profiles different to those so far isolated directly from venoms. A 
combination of approaches employing radioligand binding and electrophysiology with 
chimeric channels (Chen et al., 2006; Salinas et al., 2006), mutagenesis (Saez et al., 2015) and 
co-crystal structures (Baconguis and Gouaux, 2012; Dawson et al., 2012) has shown that 
PcTx1 binds to the acidic pocket with the majority of contacts on the thumb domain, with 
residues on α helix 5 being particularly critical. The thumb region is known to be important for 
proton binding and subsequent gating of the channel (Ramaswamy et al., 2013), consistent 
with PcTx1 mimicking the action of protons and inhibiting ASIC1a via stabilising the 
desensitised state (Chen et al., 2005).  
 
2.1.2. PcTx1 and structural insights into ASICs 
Two groups independently solved the PcTx1-cASIC1 crystal complex in mid 2012 
(Baconguis and Gouaux, 2012; Dawson et al., 2012), and these were the first ligand bound 
structures of ASICs (Figure 1C). Dawson et al. used the non-functional cASIC1 construct at 
pH 5.5, which resulted in a channel structure almost identical to the apo structure of this 
construct. This study provided the first detailed picture of the PcTx1 binding site but 
unfortunately little new information on different channel states. In contrast Baconguis and 
Gouaux used the ∆13 cASIC1 functional construct (at pH 7.25 and 5.5), and were able to 
produce crystals in what appear to be two different open conformations. The pH 7.25 structure 
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was proposed to be non-selective for monovalent cations, whilst the pH 5.5 structure to be Na+-
selective (PNa/PK = 10/1, i.e. the same selectivity as seen for typical ASIC currents). It remains 
to be seen if there is any correlation between the two channel states observed independently in 
the functional studies by Smith and Gonzales (2014) and these structural studies, and what 
affect the ∆13 truncation has on channel structure-function. 
At the time, the low pH structure was proposed to be the ‘open’ state of the channel. There 
is very little difference in the extracellular domain between the ‘open’ and desensitised states, 
however significant conformational rearrangements occur in the TM domains, as previously 
predicted from accessibility studies with cysteine-reactive reagents (Li et al., 2011). The 
available crystallographic data suggested desensitisation gating (open to desensitised 
transition) to involve binding of stimulatory ligands (protons and/or PcTx1) to the thumb and 
finger, that results in rotational and flexing movement of the TM domains mediated via the 
wrist and lower palm. How well these structural rearrangements translate to changes that occur 
during activation gating remains unexplained. Further details on the structure of the pore and 
‘open’ state of ASICs were revealed when the MitTx-cASIC1 crystal complex was solved two 
years later in 2014 (See Section 2.4.2). 
 
2.1.3. The neuroprotective properties of PcTx1 
Being the first-discovered, selective inhibitor of ASICs, PcTx1 has been extensively used in 
animals to help determine the role of ASIC1a in a wide variety of physiological and 
pathological processes such as pain, anxiety, depression, epilepsy (with contrasting results) and 
respiratory control (Baron et al., 2013; Baron and Lingueglia, 2015; Wemmie et al., 2006; 
Wemmie et al., 2013). However, the standout condition in which PcTx1 has played a role in 
validating ASIC1a as a promising therapeutic target is ischaemic stroke. A key role for ASIC1a 
in the neuronal cell death following ischemic stroke was first reported in 2004 (Xiong et al., 
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2004). Xiong and colleagues provided evidence from a combination of genetic and 
pharmacological approaches using the non-selective ASIC inhibitor amiloride as well as 
PcTx1. However, instead of using pure peptide, “PcTx1 venom” was employed in both the in 
vitro and in vivo aspects of the study. The crude tarantula venom that contains PcTx1 (at only 
0.4%) is complex and contains a multitude of other bioactive peptides (see (McCarthy et al., 
2015)). “PcTx1 venom” was also used in a follow up study that demonstrated a substantial 
therapeutic time window for ASIC inhibition (up to five hours post insult) as well as 
neuroprotective efficacy when delivered intranasally (Pignataro et al., 2007). Pure PcTx1 has 
since been shown to be neuroprotective in both rodent and porcine models of cerebral ischemia 
when administered 30 min prior to induction of stroke (Duan et al., 2011; Yang et al., 2011). 
More recently a study confirmed that a single dose of pure PcTx1 (1 ng/kg, i.c.v. 2 hours post 
stroke) does indeed provide substantial neuronal and functional protection in ischemic stroke in 
conscious hypertensive rats (McCarthy et al., 2015). Promisingly, none of the studies using 
PcTx1 in vivo reported any obvious adverse effects let alone acute toxicity, consistent with the 
original CNS toxicity test in mice by Escoubas et al. (Escoubas et al., 2000). Thus PcTx1 has 
proved to be an important tool in the identification and confirmation of ASIC1a as a stroke 
target. 
 
2.2. Hm3a 
At the same time as the identification of PcTx1, a second, homologous peptide was 
identified from tarantula venom (Escoubas unpublished). However, it remained unstudied and 
unreported until now. In this issue of Neuropharmacology we present the characterisation of pi-
TRTX-Hm3a (Hm3a) isolated from the Togo starburst tarantula (Heteroscodra maculata) (Er 
et al., 2017). Hm3a has five amino acid substitutions compared to PcTx1 and is shorter by 
three residues at the C-terminus (Figure 2A). Of these residues, only the R28K substitution lies 
within the active site, however is a conservative change that has little apparent effect on 
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potency. To further understand the ASIC1 isoform selectivity and peptide-channel interaction 
surface for Hm3a and PcTx1, we studied crystal contact residues on the complementary 
surface to the thumb domain (i.e., the loop between β-strands 3 and 4 in the palm domain of 
the adjacent subunit). Rat ASIC1a was mutated to mimic ASIC1b within the 19-residue region 
N-terminal to the ASIC1a/1b splice site known to be crucial for PcTx1 function (Chen et al., 
2006; Salinas et al., 2006). Testing of these mutants for sensitivity to PcTx1 identified Arg175 
and Glu177 (Cys and Gly in ASIC1b, respectively) to play a key role in the subtype dependent 
effects of Hm3a. Er et al. also showed that Hm3a potentiates acid-induced currents in oocytes 
co-injected with rASIC1a and rASIC1b (Er et al., 2017), an effect we observed for PcTx1 
(unpublished observations), which has not previously been noted.  
Interestingly, this study performed in vitro stability assays and revealed that PcTx1 is not as 
biologically stable as one might assume for an ICK peptide whereas Hm3a is. Hm3a was 
extremely stable in human serum over 48 hours (~87% remaining), whereas ~35% of PcTx1 
remained over the same assay time. Hm3a had very little breakdown over 48 hours at 55 °C, 
however PcTx1 showed some loss (~24%). The superior stability of Hm3a over PcTx1, 
coupled with the similar pharmacology of the peptides makes Hm3a a potentially more 
attractive ASIC tool for in vivo studies.  
 
2.3. Hi1a 
The recent discovery of a third ASIC inhibitor from spider venom has defined a novel class 
of ASIC modulatory peptides with unique structural and pharmacological properties. The 
sequence of Hi1a was noticed during analysis of the venom-gland transcriptome of an 
Australian funnel-web spider (Hadronyche infensa) as its N-terminus bore a striking similarity 
to PcTx1 (62% identity). However, unlike PcTx1, Hi1a is almost twice the length at 75 
residues, with the C-terminal half also resembling PcTx1 (50% identity) (Chassagnon et al., 
2017) (Figure 2A). Recombinant production of the peptide allowed structural and functional 
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studies confirming that Hi1a is indeed a highly potent inhibitor of ASIC1a (IC50 of 400–500 
pM) and takes the form of two ICK motifs in series (Figure 2B), similar to the TRPV1 agonist 
DkTx (Bohlen et al., 2010). Despite Hi1a’s high sequence identity with PcTx1 and Hm3a, it 
has a unique pharmacological profile against ASICs. In contrast to the single ICK peptides, 
which affect ASIC1 desensitisation gating (either facilitating it, ASIC1a, or hindering it, 
ASIC1b) in a pH-dependent and rapidly reversible manner, Hi1a selectively inhibits the 
activation of ASIC1a in a slowly reversible manner and has little effect on ASIC1b up to 1 µM. 
Thus, Hi1a is the most potent and selective inhibitor of ASIC1a discovered to date making it a 
valuable research tool. Indeed, the initial assessment of its in vivo efficacy in ischaemic stroke 
showed that a single dose of Hi1a (2 ng/kg, i.c.v.) provides a very substantial level of 
neuroprotection even when administered up to eight hours post-insult. Preliminary structure-
activity studies show that the binding site of Hi1a overlaps that of PcTx1 and suggest that the 
relative orientations of the two knot motifs is important for its unique mechanism and kinetics 
(Chassagnon et al., 2017). The combined ability of Hi1a to stabilise the resting state of ASIC1a 
and dissociate slowly suggest that it will be very useful in ASIC structural studies as well as 
localisation studies of the channel.  
 
2.4. APETx2 
2.4.1. The first selective ASIC3 inhibitor 
APETx2 is a 42-residue peptide, isolated from extracts of the sea anemone Anthopleura 
elegantissima (Figure 2A). It was the first potent and selective inhibitor of ASIC3-containing 
channels with an IC50 of 63 nM for homomeric rASIC3 and 0.1–2 µM for heteromeric rASIC3 
containing channels (Diochot et al., 2004). The peptide is slightly less potent on the human 
ASIC3 subtype with an IC50 of 175 nM. APETx2 inhibits the typical transient acid-induced 
current and the pH 7.0 evoked window (sustained) current of ASIC3 (Deval et al., 2011), as 
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well as the alkali-induced current of hASIC3 (Delaunay et al., 2012), but does not inhibit the 
larger sustained current evoked at pHs lower than 5.0 (Diochot et al., 2004). The structure of 
APETx2 consists of a compact hydrophobic core composed of a four-stranded β-sheet 
containing three disulfide bonds, resembling a defensin-like fold (Figure 2B & 3D) (Chagot et 
al., 2005; Jensen et al., 2014). At higher concentrations APETx2 also inhibits the voltage-gated 
sodium channels NaV1.2, NaV1.6, and NaV1.8 with varying degrees of potency depending on 
subtype and study (Blanchard et al., 2012; Peigneur et al., 2012). Additional off target effects 
have been shown with APETx2 also inhibiting the cardiac hERG channel in the low 
micromolar range (Jensen et al., 2014), demonstrating that this prototypical “selective” ASIC3 
inhibitor is not as selective as at first thought.  
The pharmacophore of APETx2 for ASIC3 has recently been shown to comprise a 
contiguous surface made up of loops 2 and 4 and the N-terminus (Figure 1A, 3D) (Anangi et 
al., 2012; Jensen et al., 2014). Mutagenesis of APETx2 and its interaction with hERG has also 
been studied in some detail showing a partial overlap in the pharmacophore with that of ASIC3 
(Jensen et al., 2014). Nevertheless, the molecular details of the interaction between APETx2 
and ASIC3 (or indeed its off target channels), including the mechanism of action and binding 
sites have not been extensively studied. It has been speculated that APETx2 binds to the acidic 
pocket and shifts the channel's apparent affinity for protons (Baron et al., 2013) in the opposite 
direction to that of PcTx1. More recently a docking study predicted the binding site to be either 
the upper thumb area, or slightly above the transmembrane domains, between the wrist and 
palm region (Rahman and Smith, 2014). However, there is currently no published functional 
evidence to support either of these hypotheses. Given that APETx2 is still the most potent 
ligand available to study ASIC3, unequivocally determining it binding site and mechanism of 
action are crucial to develop more selective analogues and further our understanding of ASIC3 
structure and in vivo function. 
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2.4.2. An APETx2 analogue from another sea anemone 
pi-AnmTX Hcr 1b-1 (also Hcr 1b-1) is a peptide related to APETx2 (51% identity, Figure 
2A) and was isolated from the sea anemone Heteractis crispa (Kozlov et al., 2012). The 
peptide inhibits the transient current of hASIC3 expressed in Xenopus oocytes with an IC50 
value of 5.5 µM. Although much less potent than APETx2 (~35 fold) and significantly 
different in sequence, it is interesting to note that the peptides share identity for much of the 
APETx2 pharmacophore for ASIC3. The sequence differences between these peptides and 
their comparative activity on APETx2’s off targets should provide some novel insight to 
structural elements that give rise to the ASIC3 activity profile. 
 
2.4.3. APETx2 in peripheral pain 
The use of APETx2 in vivo has been key in establishing the role of ASIC3 as a sensor of 
acid-induced and post-operative pain (Deval et al., 2011), and demonstrating its involvement in 
inflammatory pathways (Deval et al., 2008). In agreement with this, several independent labs 
have reported that APETx2 is analgesic in rat models of inflammatory and osteoarthritic pain 
(Deval et al., 2008; Ikeuchi et al., 2009; Karczewski et al., 2010). Peripheral application of 
APETx2 also reduces mechanical hypersensitivity in non-inflammatory muscular pain models 
and angina (Ikeuchi et al., 2008; Yagi et al., 2006). In a study assessing the biological stability 
of APETx2 and cyclised analogues, the wild-type peptide was almost completely broken down 
in simulated gastric fluid within 20 minutes while the stability in serum was not assessed 
(Jensen et al., 2012). Despite the promising results from animal pain models, the biological 
stability and off target profile of APETx2 would appear to greatly restrict its value as a 
therapeutic lead candidate.  
 
2.5. MitTx 
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2.5.1. A potent ASIC agonist that causes pain 
MitTx was isolated from the Texas coral snake (Micrurus tener tener) based on its ability to 
robustly activate a population of rat cultured sensory neurons (Bohlen et al., 2011). The active 
toxin is a 1:1 complex of two non-covalently bound subunits — MitTx-α consisting of a 60-
residue Kunitz type peptide, and MitTx-β, which is a 120-residue phospholipase A2 (PLA2)-
like protein (Figure 2A). Although inactive as individual components, the heterodimer is a 
potent pH-independent agonist of ASIC1a and ASIC1b (EC50 9 and 23 nM, respectively), 
whilst being considerably less potent at ASIC3 (EC50 830 nM). MitTx is a weak outright 
agonist at ASIC2a (i.e., does not directly activate the channel to more than 10% of pH-evoked 
current size), however it is a strong potentiator of this channel (amplifying the proton-induced 
current by ~3 orders of magnitude) by shifting the activation curve to more alkaline pH.  
The bite of a Texas coral snake is known to be extremely painful, and often requires 
hospitalisation and administration of opiates (Morgan et al., 2007; Nishioka et al., 1993). 
Peripheral administration of MitTx into mice hindpaws evoked robust nocifensive responses 
(Bohlen et al., 2011). This pain behaviour was also observed in ASIC3-/- mice, but not in 
ASIC1-/- mice. Furthermore, analysis of the MitTx activity in trigeminal neurons from wild-
type, ASIC1-/-, and ASIC3-/- mice revealed the activation was abolished only in ASIC1-/- 
animals. These experiments provided the first clear evidence of the involvement of ASIC1 in 
peripheral nociceptive pathways. Previous studies using PcTx1 and various genetic models 
have yielded inconsistent phenotypes and somewhat inconclusive results in regards to the role 
of ASIC1 in peripheral nociception (Lin et al., 2015). Thus, the discovery of the first potent 
ASIC1 agonist provided a clear leap in knowledge in this field. However, MitTx is a potent 
agonist of both ASIC1a and ASIC1b channels, making it unclear which subtype is a more 
important target for peripheral analgesia.  
 
2.5.2. The true open state structure of ASICs? 
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The most recent structures of cASIC used the ∆13 cASIC1 construct and exploited the fact 
that it was sensitive to the agonist properties of MitTx (Baconguis et al., 2014). The MitTx-
cASIC1 co-crystal complex (Figure 1D) is significantly different to previous ASIC structures 
in the TM regions, and has been interpreted as the open state that most likely resembles the 
native Na+-conducting state. In this structure there is a break in the α helix of the second TM 
domain (TM2) that causes it to adopt an extended conformation. This structural rearrangement 
allows the top half of TM2 from one subunit to interact with the bottom half of TM2 from an 
adjacent subunit (See Figure 1A and 1D). Interestingly, the TM domain swap was also 
observed in the 2009 desensitised apo structure upon reanalyses of the electron densities 
(Gonzales et al., 2009), but not in either of the PcTx1 complex structures (Baconguis and 
Gouaux, 2012). This swapping of TM domains results in a continuous structure that contains a 
GAS motif that is important for creating the Na+-selectivity filter of ASICs (Carattino and 
Della Vecchia, 2012; Kellenberger et al., 2001; Kellenberger et al., 1999; Li et al., 2011). Cs+-
soaked MitTx-cASIC1 crystals revealed coordination of Cs+ ions by carbonyl atoms of Gly443 
of the GAS motif. The pore dimensions in the selectivity filter of these crystals match that of a 
hydrated Na+ ion extremely well, suggesting that the TM orientations in this structure may be 
functionally relevant and provide a barrier mechanism for ion selectivity of ASICs whereby the 
pore is large enough to admit a hydrated Na+ ion but exclude a hydrated K+ ion. This is 
inconsistent with the findings of Yang and Palmer who, using hASIC1a, showed that when Na+ 
is absent, K+ could freely pass through the channel (Yang and Palmer, 2014). This argues 
against a barrier mechanism for ion selectivity (or suggests that pore size is not the only factor 
regulating ion conductance), at least for the human isoform, and highlights that care should be 
taken when applying observations across specific species or subtype variants of ASICs. 
The MitTx-cASIC1 crystal structure not only provided possible further insights into channel 
gating, but also revealed the expansive MitTx binding site, and both peptide and channel 
residues that could be functionally critical. In contrast to PcTx1 and mambalgins that bind at 
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the interface between adjacent subunits, MitTx binds almost exclusively to a single subunit 
from the wrist to the knuckle, along the entire length of the thumb domain. There is a caveat 
here in that the cASIC-MitTx complex crystallised as an ASIC monomer (Baconguis et al., 
2014) as opposed to a trimer thus there is not much choice but to bind to a single subunit 
(Baconguis and Gouaux, 2012). Nevertheless, there is an overlap in the binding site of the β 
subunit of MitTx and PcTx1 at the acidic pocket (Figure 3A), explaining the mutually 
exclusive functional activity of these peptides observed in earlier studies (Bohlen et al., 2011). 
The α subunit binds below the β subunit towards the base of the thumb and extracellular 
domains, another region known to be important for channel gating (Li et al., 2010; Roy et al., 
2013; Springauf et al., 2011) (Figure 1D and 3A).  
The various crystal structures of ASICs, channel alone and venom peptide bound, have 
provided valuable insight into the structural basis of channel gating. Nevertheless, many details 
regarding the gating of ASICs remain to be determined. All ASIC structures solved to date 
have been of cASIC1, which can be pharmacologically quite different when compared to 
mammalian ASIC1a despite ~89% sequence identity. For example, the functional effects of 
PcTx1 are more similar for ASIC1b and cASIC1 than ASIC1a and cASIC1. And more 
strikingly, 2-guanidine-4-methylquinazoline (GMQ) has the same effect on the pH activation 
curve of ASIC3 and cASIC1 (shifting to more alkaline values) but the opposite effect on 
ASIC1a (Alijevic and Kellenberger, 2012; Smith and Gonzales, 2014). Several of the key 
questions remaining in this area are: Which ASIC subtype does cASIC1 truly resemble in 
structure and function, and what does this mean for interpreting data from mammalian 
channels in light of the cASIC structure? Is there only one true open state, or are there several 
physiologically relevant open states? And perhaps the most important unanswered question in 
regards to ASIC structure and gating: What is the conformation of the closed/resting state? As 
PcTx1 and MitTx have allowed the structural insights into the possible open states described 
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above, it is likely that a ligand able to stabilise the channel in a closed state would be of great 
use in this endeavour.  
 
2.6. Mambalgins 
2.6.1. Pharmacology and structure of mambalgins 
Mambalgins are a group of homologous peptides isolated from the venom of mamba snakes. 
Two 57-residue peptides were isolated from the black mamba (Dendroaspis polylepsis 
polylepsis) that differ by one amino acid have been named mambalgin-1 and mambalgin-2 
(Ma-1 and Ma-2, respectively) (Diochot et al., 2012). A third peptide, Ma-3, from the green 
mamba (Dendroaspis augusticeps) was also isolated and has a single mutation at position 23 
when compared to Ma-1 (Baron et al., 2013) (Figure 2A). These peptides conform to the three-
finger toxin fold (Figure 2B) and inhibit homomeric ASIC1a (rat and human IC50 3–55 and 
127 nM, respectively) and rASIC1b (IC50 44–192 nM), as well as ASIC1a- and ASIC1b-
containing heteromers with weaker potency (Diochot et al., 2012; Mourier et al., 2016; 
Schroeder et al., 2014). Mambalgins inhibit ~60% of ASIC currents in rat sensory neurons, 
whereas PcTx1 only inhibits ~40%, most likely due to the broader activity profile of 
mambalgins through ASIC1b containing channels (Diochot et al., 2012). A study using human 
stem cell-derived sensory neurons showed that Ma-1 also inhibits native human ASIC currents 
(Young et al., 2014). Although there are small discrepancies in the potency of peptides across 
platforms and publications, all three peptides have been reported to have the same overall 
pharmacological profile.  
Mambalgins are thought to preferentially bind to the closed state of ASICs and inhibit 
channels by shifting the pH-dependence of activation to more acidic pH, decreasing their 
apparent affinity for protons (Diochot et al., 2016; Salinas et al., 2014). Chimeric studies in 
which domains of ASIC1a were swapped with ASIC2a (not sensitive to mambalgins) suggest 
that the mambalgins bind in the region of the acidic pocket, with the peptide interacting with 
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the β-ball and upper thumb of one subunit and the palm of the adjacent subunit (Salinas et al., 
2014). Single point mutants of the channel in this region were also made to identify specific 
interacting residues of which F350 on helix 5 in the thumb stands out as an important contact 
(Salinas et al., 2014; Schroeder et al., 2014). However, these studies lack the detail to explain 
the observed selectivity/potency differences between ASIC species isoform and subtypes. The 
pharmacophore of Ma-1 has also been partially determined with alanine mutants only made so 
far in loop 2. Mutating residues Phe27, Arg28, Leu32, Ile33, and Leu34 induced a significant 
decrease in potency, and this face of the peptide was determined to be the ASIC-interacting 
surface (Mourier et al., 2016) (Figure 3F), in contrast to the results of a prior docking-based 
prediction by the same group (Salinas et al., 2014). 
Unlike PcTx1 and APETx2, recombinant production of mambalgins has not been reported. 
However several elegant strategies have been developed to synthesise the peptide for structural 
and functional studies (Mourier et al., 2016; Pan et al., 2014; Schroeder et al., 2014). Two 
high-resolution NMR structures have been published and are in good agreement with one 
another, with the lower part of loop 2 showing some flexibility within the NMR ensemble (Pan 
et al., 2014; Schroeder et al., 2014). More recently crystal structures of two Ma-1 polymorphs 
were determined, showing significant structural variations compared to the NMR structures 
(Mourier et al., 2016) (see Figure 2B). In both crystal structures the lower part of loop 2 is 
extended and well defined and there was a large degree of conformational variability in loop 3. 
Of the two crystal structures, the most frequently observed and most ordered conformation of 
loop 3 was a single-turn helix. The NMR structures of this region contain a short β-sheet, and 
this conformation can also be seen as a less frequent form within the crystal structures. It must 
also be noted that for both polymorphs of the wild-type peptide, the Ma-1 molecules assembled 
together as complexes of either dimers or tetramers in a single asymmetric unit. In both 
crystals there were significant inter-molecular interactions present, which may explain the 
differences to the more flexible NMR structures, and this may result in structures where the 
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Ma-1 loops have been stabilised in non-physiologically relevant conformations. These 
differences between the NMR and crystal structures are extremely important when studying the 
functional surface of the peptide, as they yield different surface-exposed residues. This will 
have profound implications when mapping on pharmacophore residues and understanding the 
nature of the interaction of these peptides with ASICs. Unfortunately, no co-crystal structure of 
mambalgins in complex with ASICs has been reported to date. Either structural information of 
the mambalgin-ASIC interaction, or more extensive peptide and channel mutagenesis will be 
required to truly understand this interaction to facilitate design of ASIC1a or ASIC1b selective 
analogues.  
 
2.6.2. Is ASIC1b or ASIC1a important in peripheral nociception? 
The discovery that MitTx robustly elicits nocifensive (pain-related) behaviour in mice upon 
intraplantar injection highlighted ASIC1 as an important mediator of peripheral nociception. 
However, the lack of selective inhibitors of ASIC1b, and lack of peripheral analgesic activity 
of PcTx1 (Mazzuca et al., 2007) made it difficult to tease out the relative importance of 
ASIC1a and ASIC1b in peripheral pain. Ma-1 was found to be analgesic when administered 
centrally or peripherally and experiments with ASIC knockout and knockdown animals suggest 
that the central effects of Ma-1 are mediated by ASIC1a, whereas peripheral analgesia is 
mediated by ASIC1b (Diochot et al., 2012). This group has now demonstrated the analgesic 
potential of mambalgins in rodent models of thermal, inflammatory and neuropathic pain, 
however this finding has yet to be reported by any independent group (Diochot et al., 2016; 
Diochot et al., 2012).  
 
2.7. Ugr 9-1 
Sea anemones have proved to be a consistent source of ASIC ligands with the painted 
anemone (Urticina grebelnyi) yielding Ugr 9-1 (also pi-AnmTx Ugr 9a-1) (Figure 2A), a low 
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affinity inhibitor of both transient and sustained current of hASIC3 (Osmakov et al., 2013). 
The peptide reversibly and completely blocked the transient current with an IC50 of 10 µM, and 
inhibited the sustained current with maximal inhibition of ~48% and an IC50 of ~1.4 µM. No 
activity was observed at up to 50 µM on ASIC1a, ASIC1b, and ASIC2a, potentially making it 
a more selective ASIC3 inhibitor than APETx2. In this study the peptide was applied for only 
10 s before the low pH stimulus, thus, depending on its on-rate the IC50 values determined 
could be underestimating the true potency (i.e. if steady-state inhibition is not reached within 
the short application time used). The peptide was successfully produced in E. coli to assist in 
structure determination and animal studies with a final yield of ~8 mg of peptide per litre of 
culture. The NMR structure revealed a novel scaffold for short peptides named the boundless 
β-hairpin. The Ugr 9-1 structure is ‘boundless’ as the disulfide bonds do not stabilise the core 
of the peptide (no interstrand disulfides), instead one disulfide links the N-terminus to the β-
core, and another the C-terminus to a β-turn (see Figure 2B). 
Assessment of the Ugr 9-1 three dimensional surface, and sequence comparison with the 
ASIC3 inactive homologs Ugr 9-2 and Ugr 9-3 led Osmakov et al. to predict the functional 
surface to contain Phe9, His12, and Tyr24 of Ugr 9-1 (as these are the only three residues that 
are unique to Ugr 9-1 when compared to Ugr 9-2 and Ugr 9-3) (Osmakov et al., 2013). Follow 
up work from the same laboratory introduced the individual mutations T9F and Y12H into the 
inactive Ugr 9-2 to resemble the active Ugr 9-1 (Osmakov et al., 2016). The mutant peptides 
gained ASIC3 activity but were 2.2- and 1.3-fold weaker than native Ugr 9-1, respectively, 
demonstrating the importance of these residues for inhibitory activity. An N- and C-terminally 
truncated analogue of Ugr 9-1, Ugr22, was also produced and shown to be equipotent with 
native Ugr 9-1 at inhibiting ASIC3. The mechanism of action and binding site of these peptides 
is still unknown. 
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Ugr 9-1 showed analgesic effects in two models of inflammatory pain, the CFA-induced 
thermal hyperalgesia model, and the acetic acid writhing test (Osmakov et al., 2013). 
Unsurprisingly, neither of the ASIC inactive peptides Ugr 9-2 and Ugr 9-3 had any effect in the 
hyperalgesia model. Animals treated with any of the three active peptides showed no motor 
impairment or sedation, making Ugr 9-1 and Ugr22 promising tools to study ASIC3 in vivo. 
Despite their comparable potency at ASIC3, Ugr22 reversed thermal hyperalgesia with greater 
efficacy than Ugr 9-1 at 0.1 mg/kg dose (Osmakov et al., 2016) possibly due to the smaller 
mass of Ugr22, therefore higher molar dose. 
 
2.8. PhcrTx1 
PhcrTx1 (also pi-PMTX-Pcf1a) was isolated from the sea anemone Phymanthus crucifer as 
an inhibitor of ASIC currents in rat DRG neurons with an IC50 ~100 nM (Rodríguez et al., 
2014). It also partially (less than 20%) inhibits voltage-gated K+ currents in DRG neurons in 
the low micromolar range (IC50 ~3.5 µM). PhcrTx1 is a partial inhibitor of the native ASICs 
currents with maximal inhibition of ~44% at 10 µM. PhcrTx1 is fully reversible within 5 
minutes, did not affect the current desensitization rate, and was not active when applied only 
with the stimulus pH. This suggests the peptide preferentially binds to the closed state of 
ASICs and prevents activation, potentially providing another novel tool to help understand 
channel gating. Given the relative potency in inhibiting ASIC currents in rat DRGs, it would be 
of interest to determine the subtype selectivity of PhcrTx1 and its analgesic potential. PhcrTx1 
appears to be the first ICK peptide isolated from sea anemones and only shares 32% identity 
with PcTx1 (Figure 2A), however the structure or disulfide bond connectivity have not yet 
been determined experimentally. Nevertheless, molecular modeling of PhcrTx1, calculation of 
the dipole moment, and comparison with the PcTx1 pharmacophore led the Rodríguez et al. to 
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predict a cluster of basic/aromatic residues to be the functional site for ASIC activity 
(Rodríguez et al., 2014).  
 
2.9. α-Dendrotoxin 
α-Dendrotoxin (α-DTx) is another toxin isolated from the green mamba venom (same 
source as Ma-3), and is a well-known low nanomolar KV1.x channel blocker that was recently 
shown to also inhibit ASICs with weaker potency (Báez et al., 2015). The 59 amino acid 
peptide is a single Kunitz domain fold (Skarżyński, 1992), similar to the α-subunit of MitTx. 
They only share ~32% identity and 55% similarity, however four of the six identified crystal 
contacts for MitTx are similar in α-DTx raising the possibility that they may bind to a similar 
site on ASICs (albeit with different functional outcomes). α-DTx reversibly inhibited ASIC 
peak currents in rat DRG neurons with an IC50 of 800 nM. Although the binding site and 
mechanism of action have yet to be determined, α-DTx inhibition was only present when cells 
were preconditioned with peptide (applied for 20 s during conditioning at pH 7.4, and also for 
5 s during the pH 6.1 acid pulse), but not when applied only with the stimulating pH. This may 
suggest that α-DTx preferentially binds to the closed state of the channel and prevents 
activation. 
 
3. Conclusions 
Since the discovery of PcTx1 at the turn of the millennium, our understanding of ASIC 
modulating venom peptides themselves, and their use in deciphering ASIC structure-function 
and involvement pathological processes have greatly increased. It is now quite clear that as for 
many other ion channel families, animal venoms are a rich source of potent and valuable ASIC 
modulators. As detailed above, there are now ten known ASIC modulators from venoms (not 
including close homologs), so far from only three sources, spiders, sea anemones (the most 
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prolific source to date) and snakes. Despite this relatively low number (when compared to the 
number of venom peptides known to modulate NaV or KV channels), a trend is starting to 
appear. The modulators from snakes and spiders are, so far, relatively selective for ASIC1, 
while the sea anemone peptides seem to preferentially target ASIC3. Whether this holds true 
over the years to come and what it means from an ecological point of view remain to be seen. 
Whether venoms will harbour any components that have selectivity for ASIC2 (which to date 
suffers a dearth of selective tools) also remains to be seen. In the mean time we still have a lot 
to learn about the tools described above in order to maximise their value as research tools.  
Essentially all small molecule modulators of ASICs characterised have poor selectivity 
against ASIC subtypes. Given the sometimes extensive interaction surface and multi-domain 
nature of venom peptide binding, we believe these gifts from nature are our best chance at 
discovering and developing more selective pharmacological tools that can better discriminate 
between ASIC subtypes. Gaining a thorough understanding of the molecular interactions 
between selective venom peptides and ASICs will almost certainly facilitate answering some 
of the major unresolved questions in the ASIC field and may even lead to some novel 
therapeutics along the way.  
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Figures 
Table 1. Activity summary of ASIC modulators isolated from animal venoms. Values are IC50 
and EC50 values for the rat isoform unless stated otherwise. Activity is colour coded into red, 
blue, and green indicating inhibition  , potentiation  , and agonism  , respectively. 
 
Peptide  Venom source
 
Activity 
PcTx1 Spider (Psalmopoeus 
cambridgei) 
  ASIC1a ~1 and ~3 nM (rat and human) 
  ASIC1a/2a ~35–85% at 50 nM 
  ASIC1a/2b ~3 nM 
  ASIC1b ~100 nM 
  cASIC1 ~10–189 nM  
  cASIC1 ~135% at 30 nM 
Hm3a Spider (Heteroscodra 
maculata) 
  ASIC1a 1.3 and 39.7 nM (rat and human) 
  ASIC1b 46.5 and 178 nM (rat and human) 
  ASIC1a/1b 17.4 nM 
APETx2 Sea anemone 
(Anthopleura 
elegantissima) 
  ASIC3 ~60 and 175 nM (rat and human) 
  ASIC3/1a 2 µM 
  ASIC3/1b 900 nM 
  ASIC3/2b 117 nM 
Hcr 1b-1 Sea anemone 
(Heteractis crispa) 
  ASIC3 5.5 µM (human) 
MitTx Snake (Micrurus tener 
tener) 
  ASIC1a 9 nM 
  ASIC1b 23 nM 
  ASIC2a 75 nM 
  ASIC3 830 nM 
  cASIC1 ~15% at 300 nM 
Ma-1 
Ma-2 
Ma-3 
Snake (Dendroaspis 
polylepis polylepis, 
Dendroaspis 
augusticeps) 
  ASIC1a 11–55 and 127 nM (rat and human) 
  ASIC1b 44–192 nM 
  ASIC1a/1b 72 nM 
  ASIC1a/2a 252 nM 
  ASIC1a/2b 61 nM 
Ugr 9-1 Sea anemone 
(Urticina grebelnyi) 
  ASIC3 10 µM (human, peak) 
  ASIC3 1.5 µM (human, sustained) 
PhcrTx1 Sea anemone 
(Phymanthus crucifer) 
  100 nM (rat sensory neurons) 
α-DTx Snake (Dendroaspis 
augusticeps) 
  800 nM (rat sensory neurons) 
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Figure 1. ASIC gating conformations, domain organisation, and venom peptide binding sites 
and functional summary. (A) cASIC1 structure in the apo, desensitised state without any 
peptide bound (PDB code 4NYK; (Gonzales et al., 2009)), with domains of a single subunit 
within the trimer colour coded. (B) The closed state is yet to be solved, and remains one of the 
biggest unknowns in the ASIC field. (C) PcTx1 bound to cASIC1 at low pH (PDB code 4FZ1; 
(Baconguis and Gouaux, 2012)), and (D) MitTx bound to cASIC1 (PDB code 4NTW; 
(Baconguis et al., 2014)), where both structures were reported at the time of publication to be 
in the open state. However, there are clear differences in the TM region and it is now thought 
the MitTx most faithfully represents the Na+ conductive, proton-gated open state of ASICs. 
ASIC modulators are shown next to the binding state each peptide favours, for the subtype 
shown in brackets.   in red indicates inhibitors,   in blue potentiators of pH-gated currents, 
and   in green direct agonists of the ASIC subtype in brackets for each ligand. Peptide 
binding sites are in italicised bold, and the grey lines depict the TM region based on the 
hydrophobicity of the protein surface. Note the functional information listed for each ligand is 
not complete and is a simplified summary; please refer to the text and Table 1 for more details.  
 
Figure 2. Venom peptide modulators of ASICs. (A) Amino acid sequence of venom peptides 
grouped with homologues where present. Differences in sequences are indicated by grey 
boxes, and active sites by triangles above the pharmacophore residue. (B) Three dimensional 
structure of PcTx1 (PDB code 2KNI;(Saez et al., 2011)), APETx2 (PDB code 2MUB; (Jensen 
et al., 2014)), Hi1a (PDB Code 2N8F; (Chassagnon et al., 2017)), Ma-1 (PDB codes 5DU1, 
5DZ5; (Mourier et al., 2016)), Ma-2 (PDB code 2MFA; (Schroeder et al., 2014)), MitTx (PDB 
code 4NTW; (Baconguis et al., 2014)), Ugr 9-1 (PDB code 2LZO; (Osmakov et al., 2013)), 
and α-DTx (PDB code 1DTX; (Skarżyński, 1992)). All peptides are shown in the same scale 
and disulfide bonds shown in red. Structures are not available for all peptides and have only 
been shown where available. 
 
Figure 3. Summary of the active surface of ASIC targeting peptides derived from 
crystallography and mutagenesis data. (A) Two subunits of cASIC1 are shown as surface 
representations with the domains colour coded as per Fig. 1. The partially overlapping binding 
orientations of PcTx1 (grey) and MitTx (blue and cyan) are shown as peptide backbones. The 
subunit interface corresponding to the acidic pocket is also highlighted. (B) Surface 
representation of PcTx1 (grey) bound to cASIC1 showing the extensive hydrophobic 
interaction with α helix 5 (green residues) and the basic residues (blue) that protrude into the 
acidic pocket. (C) Surface representation of PcTx1 with crystal contact residues highlighted in 
blue and red. Of these, red represents residues that are the functional pharmacophore and were 
found to make energetically important interactions for rASIC1a inhibition (these residues are 
labelled). (D) Active surface of APETx2 for rASIC3 inhibition, mutations of the red residues 
have a major impact while mutation of the orange had a less severe impact on activity. (E) 
Active surface of MitTx based on predictions from XRD crystal contacts. (F) Amino acid 
residues shown to be important for Ma-1 inhibitory activity mapped on to the NMR structure 
of Ma-2.  (NB: structures are not to scale). 
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Highlights: 
• The most potent and selective modulators of ASICs have come from animal venoms. 
• ASIC modulators have been isolated from spiders, sea anemones, and snakes. 
• Venom peptides have advanced our understanding of ASIC gating and structure. 
• Venom peptides have helped elucidate the in vitro and in vivo roles of ASICs. 
• Venom-derived modulators of ASICs are likely to play a big role in the future. 
 
